Alfresa Holdings Corp
TSE:2784
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
A
|
Alfresa Holdings Corp
TSE:2784
|
464.7B JPY |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
115.3B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.5B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
70B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
51.9B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.8B AUD |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.8B CNY |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.8B CNY |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66.1B HKD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Alfresa Holdings Corp
Glance View
In the bustling world of pharmaceuticals and healthcare, Alfresa Holdings Corp. stands as a notable player, weaving a complex web that connects various facets of the medical industry in Japan and beyond. Founded in 2003 as a result of a merger, Alfresa has carved a niche for itself in the logistics and distribution sector of pharmaceuticals. The company's core strength lies in its ability to streamline the journey of medicinal products from manufacturers to healthcare providers. This massive undertaking is facilitated by an intricate network of strategic partnerships and a robust supply chain, ensuring that pharmacies, hospitals, and clinics receive the necessary products promptly and efficiently. Alfresa’s revenue streams are as diversified as the products it handles. Beyond its role as a distributor, the company has expanded into the manufacturing of its own pharmaceuticals, further solidifying its position in the market. This vertical integration allows it not only to distribute third-party products but to add value by developing and marketing its proprietary offerings. In an industry rife with competition and regulatory challenges, such a strategy provides a dual advantage: a stable supply for its distribution networks and an additional revenue channel. Alfresa's commitment to innovation and efficiency has enabled it to maintain steady growth, balancing between its traditional distribution roots and its forays into pharmaceutical production, thus affirming its status as a key cog in the healthcare industry’s machine.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Alfresa Holdings Corp is 1.1%, which is above its 3-year median of 1%.
Over the last 3 years, Alfresa Holdings Corp’s Net Margin has increased from 1.1% to 1.1%. During this period, it reached a low of 0.8% on Aug 30, 2025 and a high of 1.2% on Dec 31, 2024.